Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists

Metabolism: Clinical and Experimental

Volumn 66, Issue , 2017, Pages 64-68

  Polyzos, Stergios A ^a   Bugianesi, Elisabetta ^b   Kountouras, Jannis ^a   Mantzoros, Christos S ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF TURIN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INT 131; LIGAND; LIPOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINOLINE DERIVATIVE; SULFONAMIDE;

DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; HUMAN; LIPID ANALYSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; ANIMAL; HYPERLIPIDEMIA; MEDICAL RESEARCH; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIGANDS; LIPOTROPIC AGENTS; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR GAMMA; QUINOLINES; SULFONAMIDES; THIAZOLIDINEDIONES;

EID: 84994108643     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.08.001     Document Type: Editorial

References (47)

1. [1] Bugianesi, E, Rosso, C, Cortez-Pinto, H, How to diagnose NAFLD in 2016. J Hepatol 65 (2016), 643–644.
2. [2] Bugianesi, E, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. Diabetologia 59 (2016), 1145–1147.
3. [3] Fazel, Y, Koenig, AB, Sayiner, M, Goodman, ZD, Younossi, ZM, Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1017–1025.
4. [4] Zoller, H, Tilg, H, Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 65 (2016), 1151–1160.
5. [5] Khan, RS, Newsome, PN, Non-alcoholic fatty liver disease and liver transplantation. Metabolism 65 (2016), 1208–1223.
6. [6] Petta, S, Valenti, L, Bugianesi, E, Targher, G, Bellentani, S, Bonino, F, A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis 48 (2016), 333–342.
7. [7] Vanni, E, Marengo, A, Mezzabotta, L, Bugianesi, E, Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis 35 (2015), 236–249.
8. [8] Marengo, A, Jouness, RI, Bugianesi, E, Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis 20 (2016), 313–324.
9. [9] Polyzos, SA, Kountouras, J, Zavos, C, The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia, 13, 2009, 127.
10. [10] Polyzos, SA, Mantzoros, CS, An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism 64 (2015), 937–942.
11. [11] Dongiovanni, P, Valenti, L, Genetics of nonalcoholic fatty liver disease. Metabolism 65 (2015), 1026–1037.
12. [12] Mahady, SE, George, J, Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1172–1182.
13. [13] Polyzos, SA, Kountouras, J, Zavos, C, Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72 (2009), 299–314.
14. [14] Spahis, S, Delvin, E, Borys, JM, Levy, E, Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal, 2016, 10.1089/ars.2016.6776.
15. [15] Polyzos, SA, Kountouras, J, Mantzoros, CS, Adipokines in nonalcoholic fatty liver disease. Metabolism 65 (2016), 1062–1079.
16. [16] Petrasek, J, Csak, T, Ganz, M, Szabo, G, Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 28:Suppl. 1 (2013), 93–98.
17. [17] Goel, A, Gupta, M, Aggarwal, R, Gut microbiota and liver disease. J Gastroenterol Hepatol 29 (2014), 1139–1148.
18. [18] Polyzos, SA, Kountouras, J, Deretzi, G, Zavos, C, Mantzoros, CS, The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med 12 (2012), 68–82.
19. [19] Karajamaki, AJ, Bloigu, R, Kauma, H, Kesaniemi, YA, Koivurova, OP, Perkiomaki, J, et al. Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes. Metabolism, 2016, 10.1016/j.metabol.2016.06.009.
20. [20] Du, T, Sun, X, Yuan, G, Zhou, X, Lu, H, Lin, X, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism 65 (2016), 1391–1398.
21. [21] Cusi, K, Orsak, B, Bril, F, Lomonaco, R, Hecht, J, Ortiz-Lopez, C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med, 2016, 10.7326/M15-1774.
22. [22] Mantovani, A, Zoppini, G, Targher, G, Golia, G, Bonora, E, Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Investig 35 (2012), 215–218.
23. [23] Lallukka, S, Yki-Jarvinen, H, Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 30 (2016), 385–395.
24. [24] National Cholesterol Education Program expert p, Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002), 3143–3421.
25. [25] Katsiki, N, Mikhailidis, DP, Mantzoros, CS, Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
26. [26] Toth, PP, Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 12 (2016), 171–183.
27. [27] Wadhera, RK, Steen, DL, Khan, I, Giugliano, RP, Foody, JM, A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10 (2016), 472–489.
28. [28] Polyzos, SA, Kountouras, J, Zavos, C, Deretzi, G, Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46 (2012), 272–284.
29. [29] Zhang, QQ, Lu, LG, Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol 3 (2015), 78–84.
30. [30] Tziomalos, K, Athyros, VG, Paschos, P, Karagiannis, A, Nonalcoholic fatty liver disease and statins. Metabolism 64 (2015), 1215–1223.
31. [31] Polyzos, SA, Mantzoros, CS, Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism 65 (2016), 1297–1306.
32. [32] Lutchman, G, Modi, A, Kleiner, DE, Promrat, K, Heller, T, Ghany, M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46 (2007), 424–429.
33. [33] Ratziu, V, Charlotte, F, Bernhardt, C, Giral, P, Halbron, M, Lenaour, G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
34. [34] EASL–EASD–EASO, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59 (2016), 1121–1140.
35. [35] Lewis, JD, Ferrara, A, Peng, T, Hedderson, M, Bilker, WB, Quesenberry, CP Jr., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34 (2011), 916–922.
36. [36] Higgins, LS, Mantzoros, CS, The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer. PPAR Res, 2008, 2008, 936906.
37. [37] Dunn, FL, Higgins, LS, Fredrickson, J, DePaoli, AM, Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J Diabetes Complicat 25 (2011), 151–158.
38. [38] DePaoli, AM, Higgins, LS, Henry, RR, Mantzoros, C, Dunn, FL, Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?. Diabetes Care 37 (2014), 1918–1923.
39. [39] Xue, L, Zhu, XH, Yang, XF, Bao, XC, Gao, XQ, Qiu, YH, et al. Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis. Eur Rev Med Pharmacol Sci 19 (2015), 322–327.
40. [40] Grosso, AF, de Oliveira, SF, Higuchi Mde, L, Favarato, D, Dallan, LA, da Luz, PL, Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr, 6, 2014, 47.
41. [41] Abraldes, JG, Villanueva, C, Aracil, C, Turnes, J, Hernandez-Guerra, M, Genesca, J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150 (2016), 1160–1170 [e3].
42. [42] Alkhatatbeh, MJ, Lincz, LF, Thorne, RF, Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: an in vitro model of non-alcoholic fatty liver disease. Exp Ther Med 11 (2016), 1487–1492.
43. [43] Wang, W, Zhao, C, Zhou, J, Zhen, Z, Wang, Y, Shen, C, Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One, 8, 2013, e76538.
44. [44] Valenti, L, Bugianesi, E, Pajvani, U, Targher, G, Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver Int, 2016, 10.1111/liv.13185.
45. [45] Hazlehurst, JM, Woods, C, Marjot, T, Cobbold, JF, Tomlinson, JW, Non-alcoholic fatty liver disease and diabetes. Metabolism 65 (2016), 1096–1108.
46. [46] Athyros, VG, Mikhailidis, DP, Didangelos, TP, Giouleme, OI, Liberopoulos, EN, Karagiannis, A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22 (2006), 873–883.
47. [47] Polyzos, SA, Mantzoros, CS, Nonalcoholic fatty future disease. Metabolism 65 (2016), 1007–1016.